tranexamic acid




Concise Prescribing Info
Tranexamic acid
Haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Local fribrinolysis may occur in menorrhagia, prostatectomy & bladder surgery, haematuria, GI haemorrhage, epistaxis, ulcerative colitis, conisation of the cervix & dental extraction in patients w/ coagulopathies. General fibrinolysis may occur in prostatic & pancreatic cancer, after thoracic & other major surgery, obstetrical complications eg, ablatio placentae & post-partum haemorrhage, leukemia, liver diseases, in connection w/ thrombolytic therapy w/ streptokinase. Hereditary angioneurotic oedema.
Dosage/Direction for Use
Recommended standard dose: 5-10 mL by slow IV inj at a rate of 1 mL/min bd-tds daily. General fibrinolysis 2 amp of 5 mL by slow IV inj every 6-8 hr. Prostatectomy 1-2 amp of 5 mL by slow IV inj every 6-8 hr (1st inj to be given during the operation) for the 1st 3 days after surgery. Epistaxis Soln for inj may be applied topically by soaking a gauze strip in the soln then packing the nasal cavity. Dental extraction in patient w/ coagulopathies 10 mg/kg IV immediately before surgery. After surgery, 25 mg/kg of an oral tranexamic acid 3-4 times daily for 6-8 days. Moderate to severe renal impairment serum creatinine >500 micromol/L IV dose: 5 mg/kg daily, 250-500 micromol/L 10 mg/kg daily, 120-249 micromol/L 10 mg/kg bd.
Hypersensitivity. Active thromboembolic disease eg, DVT, pulmonary embolism & cerebral thrombosis. Subarachnoid haemorrhage.
Special Precautions
Do not use in patients w/ irregular menstrual bleeding. Patients w/ high risk for thrombosis; disseminated intravascular coagulation; convulsion. Dose reduction is recommended in patients w/ renal insufficiency. May influence the ability to drive or use machines. Pregnancy & lactation. Menorrhagic childn <15 yr.
Adverse Reactions
Nausea, vomiting, diarrhoea. Convulsion, dizziness; chromatopsia, visual impairment; embolism, hypotension (after fast inj).
Drug Interactions
Simultaneous treatment w/ anticoagulants. Caution w/ drugs that act on haemostasis. Potential risk of increased thrombus-formation eg, oestrogens. May antagonise the antifibrinolytic action w/ thrombolytics.
MIMS Class
ATC Classification
B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
Medsamic soln for inj 100 mg/mL
10 mL x 10 × 1's;5 mL x 10 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in